From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

VINDICATION (sort of): The FRC slams Crowe and its CEO over the Akazoo fraud but it lets Deloitte off the hook: this is a fail for the watchdog

By Tom Winnifrith, the Sheriff of AIM | Tuesday 10 December 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


A reminder of this Greek fraud which I was the first to expose and which I doorstepped in Athens almost a decade ago. The company was then called InternetQ (INTQ) and was listed on AIM and Deloitte signed off on its books which were sheer fiction. Its sales were made up and it was a 100% fraud. Having proved that on this website, the UK regulators did SFA and InternetQ was taken private with the assistance of Martin Hughes of Tosca Fund and rebranded as Akazoo. Three years later it listed in New York, Gabriel Grego credited me as he did a new dossier, US Regulators acted at once, not being pussies like their counterparts in London, and the whole con collapsed..
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:


Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 00:04:55